These findings, coupled with the preclinical data with CBS inhibition in DS cells and DS rodent models may be a clinically relevant pathogenetic factor in DS, especially in the context of metabolic and bioenergetic imbalance and impaired neuronal function and neurocognition. This evidence concerns the gene CBS and Dravet syndrome.